A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting av integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy.

Authors : Wirth M, Heidenreich A, Gschwend JE, Gil T, Zastrow S, Laniado M, Gerloff J, Zühlsdorf M, Mordenti G, Uhl W, Lannert H
Year : 2014
Journal : Eur Urol
Volume : 65(5)
Pages : 897-904